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 2 
ABSTRACT 17 
Calcineurin (Cn) is a calcium-activated serine/threonine protein phosphatase that is broadly 18 
implicated in diverse cellular processes, including the regulation of gene expression. During 19 
skeletal muscle differentiation, Cn activates the NFAT transcription factor but also promotes 20 
differentiation by counteracting the negative influences of protein kinase C beta (PKC) via 21 
dephosphorylation and activation of BRG1, an enzymatic subunit of the mammalian SWI/SNF 22 
ATP-dependent chromatin remodeling enzyme. Here we identified four major temporal patterns 23 
of Cn-dependent gene expression in differentiating myoblasts and determined that Cn is broadly 24 
required for the activation of the myogenic gene expression program. Mechanistically, Cn 25 
promotes gene expression through direct binding to myogenic promoter sequences and 26 
facilitating the binding of BRG1, other SWI/SNF subunit proteins, and MyoD, a critical lineage 27 
determinant for skeletal muscle differentiation. We conclude that the Cn phosphatase directly 28 
impacts the expression of myogenic genes by promoting ATP-dependent chromatin remodeling 29 
and formation of transcription-competent promoters.  30 
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 3 
INTRODUCTION 31 
Myoblast differentiation is an essential process during skeletal muscle development 32 
where mononuclear myoblasts withdraw from the cell cycle and undergo fusion and other 33 
morphological changes to form multi-nucleated myotubes. This process is coordinated by the 34 
family of myogenic regulatory factors (MRFs) that include MyoD, myogenin, Myf5, and Mrf4 in 35 
cooperation with the MEF family of transcription factors and other auxiliary transcriptional 36 
regulators. MRFs regulate the commitment, determination, and differentiation of skeletal muscle 37 
progenitor cells. The ability of MRFs to drive the myogenic gene expression needed for 38 
differentiate requires remodeling of chromatin at target genes that depends on the recruitment of 39 
histone modifying and chromatin remodeling complexes that alter nucleosome structure and the 40 
local chromatin environment (1-3). 41 
The SWI/SNF (SWItch/Sucrose Non-Fermentable) complexes are large, multiprotein, 42 
ATP-dependent chromatin remodeling enzymes (4-6) that alter nucleosome structure to promote 43 
transcription, replication, recombination and repair (7-10). The chromatin remodeling activity of 44 
the SWI/SNF enzyme is required for the initiation of many developmental and differentiation 45 
programs (11-14) including activation of myogenic genes upon differentiation signaling (15, 16). 46 
Mammalian SWI/SNF complexes contain one of two related ATPase subunits, either Brahma 47 
related gene 1 (Brg1) or the ATPase Brahma (Brm), and a collection of at least 9 to 12 associated 48 
protein known as Brg1/Brm-associated factors (Bafs) (4, 17, 18). Mammalian SWI/SNF enzyme 49 
function can be influenced by the assembly of different combination of Baf subunits around the 50 
different ATPases (12, 19). Furthermore, signal transduction pathways promote specific 51 
posttranslational modifications of SWI/SNF subunit proteins that influence enzyme activity (15, 52 
20-23). In skeletal muscle differentiation, the p38 mitogen–activated protein kinase (MAPK) 53 
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 4 
phosphorylates the Baf60c subunit, which then allows the recruitment of the rest of SWI/SNF 54 
remodeling complex to myogenic promoters (24). Our group previously showed that casein 55 
kinase 2 (CK2) phosphorylates Brg1 to regulate Pax7 expression and to promote myoblast 56 
survival and proliferation (21), while protein kinase C 1 (PKC1) phosphorylates Brg1, which 57 
represses chromatin remodeling function and, consequently, myogenesis (20). 58 
Calcineurin (Cn) is a serine/threonine phosphatase that is regulated by changes in the 59 
intracellular concentration of Ca
2+
 (25). Cn is a heterodimer formed by association of catalytic 60 
subunit A (CnA) and regulatory subunit B (CnB) (26, 27). Its mechanism of action has been 61 
characterized extensively in lymphocytes, where activated Cn dephosphorylates Nuclear Factor 62 
of Activated T-cell (NFAT) transcription factors. Dephosphorylated NFAT translocates to the 63 
nucleus and binds to promoter regions of target genes to regulate gene expression (28-31). In 64 
skeletal muscle, Cn-dependent binding of NFAT to target promoters controls skeletal muscle 65 
fiber type and primary muscle fiber number during development (32, 33) and growth of 66 
multinucleated muscle cells (34-38). Cn is also required for the initiation of skeletal muscle 67 
differentiation (39), by mechanisms that are independent of NFAT (40, 41). More recently, we 68 
reported novel functions for Cn in chromatin remodeling. We showed that Cn is bound to 69 
Brg1 at the myogenin promoter and that it dephosphorylates Brg1 shortly after cells start the 70 
differentiation process to positively promote differentiation (20).  71 
The aim of the current study was to explore the global effect of Cn on gene expression 72 
in myoblasts. We demonstrate that inhibition of Cn in myoblasts globally down-regulates 73 
expression of genes important for muscle structure and function. We identified four major 74 
temporal patterns of Cn-dependent gene expression. Mechanistically, we show that Cn acts as 75 
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 5 
a chromatin binding regulatory protein, interacting with Brg1 to facilitate SWI/SNF enzyme 76 
and MyoD binding to myogenic gene regulatory sequences.  77 
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 6 
RESULTS 78 
RNA-seq identification of genes differentially expressed in myoblasts treated with calcineurin 79 
inhibitor FK506 80 
To better understand the involvement of calcineurin in the gene regulation program 81 
underlying myogenesis, we compared the transcriptomes of C2C12 myoblasts at three time 82 
points of differentiation (0, 24, and 72 h post-induction of differentiation) in cells treated with 83 
the Cn inhibitor, FK506, with those of control cells. FK506 inhibits the phosphatase activity of 84 
Cn by binding to the immunophilin FKB12; the drug-bound FKB12 binds to and blocks Cn 85 
function (28). C2C12 myoblasts treated with FK506 showed significant inhibition of myotube 86 
formation at 48 and 72h time points compared to the DMSO control, confirming prior results 87 
demonstrating that inhibition of Cn activity blocked myoblast differentiation (Fig. 1A; (39-41)). 88 
Myogenic gene expression is temporally regulated, with different genes expressed with different 89 
kinetics during differentiation (42-44). We analyzed gene expression 24 and 72 h after the 90 
induction of differentiation to distinguish the impact of Cn inhibition on genes expressed at early 91 
or late times of myogenesis.  92 
At 24h post-differentiation, 156 genes were differentially expressed in the presence of 93 
FK506 [false discovery rate (FRD) < 0.05]. Fewer genes were up-regulated (53) than were 94 
downregulated (103). At the later time point of differentiation (72h), 648 genes were 95 
differentially expressed. More genes were up-regulated (373) than were downregulated (275) 96 
(Fig. 1B, C). In confluent myoblasts at the onset of differentiation (0h), only 21 genes were 97 
differentially expressed in the presence of FK506. The complete list of differentially expressed 98 
genes determined by RNA-seq analysis is shown in Supplementary Table S1. Specific 99 
myogenic genes were identified and labeled on the volcano plots in Fig. 1B. The results indicate 100 
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 7 
that myogenic genes are downregulated by calcineurin inhibition at the 24 and 72h time points. 101 
Review of these genes determined that the genes largely encoded structural and functional 102 
proteins expressed during differentiation. Specifically, the expression of genes encoding the 103 
regulatory proteins MyoD, Myf5, Mef2A, and Mef2D were unaffected by Cn inhibition by 104 
FK506, whereas the genes encoding myogenin, Mef2C, and Six1 were noted as being sensitive 105 
to the Cn inhibitor.  The MRF4 regulator was not expressed.  In addition, we noted that none of 106 
the genes encoding NFAT proteins or genes encoding mSWI/SNF subunits showed expression 107 
changes due to Cn inhibition by FK506 (Supplementary Table S1). 108 
We performed de novo motif analysis on the differentially expressed genes. The most 109 
significantly enriched motifs at the 24h post-differentiation were for Mef2 transcription factors 110 
and E-boxes bound by the MRFs Myf5, myogenin and MyoD, and we note the continued 111 
presence of MRF and Mef2 protein binding sites at Cn-regulated genes at late times of 112 
differentiation (Fig. 1D). These findings indicate that genes that require calcineurin for 113 
expression are also regulated by myogenic regulatory factors, strongly reinforcing the connection 114 
between Cn and expression of the myogenic gene program.  115 
The top hits from a gene ontology (GO) analysis of genes up- and down-regulated by 116 
calcineurin inhibition at the 24 and 72h time points is shown in Fig. 2A. GO terms identified by 117 
side by side comparison of up- and down-regulated genes at each time point are presented in Fig. 118 
2B. Genes related to muscle differentiation and function were down-regulated in cells treated 119 
with FK506 (Figs. 2A, B). In contrast, we observed up-regulation of genes associated with 120 
ossification, response to interferons and viruses, and cardiovascular and blood vessel 121 
development. These results are consistent with documented roles for Cn in the regulation of 122 
NFAT function in these processes (45-47). These results are also consistent with our finding that 123 
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 8 
the most significantly enriched DNA binding motif at 72h post-differentiation was the interferon 124 
regulatory factor (IRF) binding sequence (Fig. 1D) and with findings that IRFs regulate 125 
expression of vascular cell adhesion molecule 1 (VCAM-1) receptor that mediates cell-cell 126 
adhesion and is important for myoblast fusion (48, 49).  127 
 128 
Global expression analysis reveals four major temporal gene expression patterns that are 129 
dependent on Cn 130 
We continued our analysis by identifying the groups of genes that showed treatment–131 
specific changes in gene expression over time. In total, 308 genes were identified. We analyzed the 132 
expression patterns of these differentially expressed genes using clusterProfiler (50). Genes 133 
differentially expressed over time were clustered into 4 major groups by k-means clustering, and 134 
graphically presented by heat map (Fig. 3A) and expression kinetics (Fig. 3B). We performed GO 135 
analysis for the differentially expressed genes in these 4 clusters to gain additional insight into the 136 
biological processes regulated by calcineurin during myoblast differentiation (Fig. 3C). Cluster 1 137 
included 95 genes that were down-regulated during differentiation but were unchanged in the 138 
presence of the Cn inhibitor. GO terms significantly enriched for this group of differentially 139 
expressed genes related to cell migration, motility and adhesion. In addition, Cluster 1 included 140 
Inhibitor of differentiation (Id) proteins 1, 2 and 3 (Supplementary Table S2). Id proteins interact 141 
with MyoD and related MRFs prior to differentiation to repress transcription activation activity. Id1 142 
and Id3 have previously been identified as genes repressed by Cn during the activation of skeletal 143 
muscle cell differentiation (41). Cluster 2 contained 80 genes that were up-regulated during 144 
myoblast differentiation but were inhibited or delayed in the presence of FK506. GO terms 145 
significantly enriched for Cluster 2 genes were related to muscle structure and function. Cluster 3 146 
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 9 
was composed of 108 genes that were expressed at relatively constant levels across the 147 
differentiation time course but that were significantly up-regulated in the presence of FK506 148 
expression. GO analysis of Cluster 3 genes identified genes implicated in immune response of cells. 149 
Cluster 4 had 25 genes with an unusual profile. These genes were up-regulated in the presence of 150 
FK506 in proliferating cells and in cells at the onset of differentiation, but were down-regulated as 151 
differentiation advanced. No specific GO terms were identified for Cluster 4. A complete list of 152 
genes in each of the clusters with their log fold change and FDR values are shown in 153 
Supplementary Table S2. These data suggests that calcineurin regulates multiple and diverse 154 
groups of genes during myoblast differentiation. We measured mRNA expression levels of two 155 
randomly chosen genes from each of clusters 1, 3 and 4 by RT-qPCR analysis (Fig. 4A) to confirm 156 
the gene expression kinetics revealed by the cluster analysis.  157 
 For further analysis, we focused on genes that were down-regulated in the presence of 158 
FK506 and are important for muscle structure and/or function (Fig. 1B). We first measured 159 
mRNA expression level of several such genes to validate RNA-seq and cluster analysis results: 160 
Myog, Ckm, Myh4, Mymk, Tnnt3, Acta1 and Cav3 were analyzed by RT-qPCR. As expected, 161 
each of these genes were increased over the course of the differentiation time course and each 162 
was significantly down-regulated by exposure to the Cn inhibitor, FK506 (Fig. 4B). These 163 
results confirmed that inhibition of Cn during myoblast differentiation impairs expression of 164 
multiple myogenic genes that are normally activated during differentiation. 165 
 166 
Inhibition of calcineurin function prevents its binding to myogenic promoters 167 
We previously showed that Cn associates with Brg1 and binds to the myogenin promoter 168 
early after the start of the differentiation process (20). We hypothesized that the same model 169 
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 10 
might be true for other myogenic genes. Alternatively, Cn may directly regulate the myogenin 170 
promoter but indirectly regulate other downstream genes and via the dependency of other genes 171 
on myogenin for completing the differentiation process (51, 52).  172 
We first determined whether the Cn inhibitor could alter the nuclear localization or 173 
chromatin association of Cn or Brg1. Immunoblot analysis of subcellular fractions is shown in 174 
Figs. 5A, B. Cn is present in both cytosolic and nuclear fractions as well as in chromatin and its 175 
localization is not changed when cells are treated with FK506. Brg1 is associated only with the 176 
nuclear and the chromatin fractions and, similar to Cn, its localization is not affected by FK506. 177 
Immunoblots of control proteins show the purity of the fractions. TATA Binding Protein (TBP) 178 
is associated with the chromatin and the nuclear fractions while GAPDH is located only in the 179 
cytosolic fraction. These data demonstrate that the effects due to inhibition of Cn activity are not 180 
due to gross mislocalization of Cn or Brg1 within the cell.  181 
We performed chromatin immunoprecipitation assays (ChIP) on the same panel of 182 
myogenic genes examined in Fig. 4B. PCR primers for ChIP were designed to amplify the E-box 183 
containing regions that bind to MyoD and MyoD-related lineage determining factors (53) within 184 
1.5 kb upstream of the TSS of each gene (Fig. 6A) and regulate gene expression (53-61). The 185 
promoter of the Pdx1 gene, which encodes the pancreatic and duodenal homeobox 1 186 
transcriptional activator, served as a negative control sequence for all ChIP experiments, as was 187 
done in prior work (62). The Pdx1 E box is bound by members of the upstream (USF) family of 188 
transcription factors (63), and is not bound by MyoD or related factors in proliferating or 189 
differentiating myoblasts (62). Pdx1 is expressed in pancreas, duodenum, gall bladder, stomach, 190 
and small intestine (64). Our RNA-seq data confirmed that Pdx1 was not expressed in 191 
proliferating or differentiating myoblasts. 192 
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 11 
Cn did not interact with myogenic genes regulatory sequences in proliferating myoblasts 193 
(GM), was weakly or not bound in undifferentiated cells at the start of differentiation (0h DM), 194 
and was bound at all myogenic gene promoters in differentiated (48h DM) cells (Fig. 6B). 195 
FK506 treatment of cells greatly reduced Cn binding. We conclude that Cn binding to myogenic 196 
promoters is a general occurrence and FK506-mediated inhibition of Cn function impairs its 197 
ability to interact with target gene promoters. The results suggest that Cn is a direct regulator of 198 
many myogenic genes. 199 
 200 
Cn inhibition blocks the interaction of the ATPase Brg1 and other subunits of the 201 
mammalian SWI/SNF complex with myogenic promoters 202 
We also performed ChIP assays to determine whether Brg1 recruitment to myogenic 203 
regulatory sequences was dependent on calcineurin. We observed recruitment of Brg1 to 204 
regulatory sequences in differentiated (48h DM) cells at all the tested myogenic genes. In cells 205 
treated with FK506, Brg1 binding was significantly diminished at all promoters (Fig. 7A). A 206 
subset of the myogenic promoters was tested for the binding of Baf170, and Baf250A/Arid1A, 207 
which are other subunits of the mammalian SWI/SNF enzyme complex. The results show that 208 
binding of these other subunits paralleled Brg1 binding in that Cn inhibition blocked interaction 209 
of these proteins to the promoters (Fig. 7B). These findings indicate that Cn activity is necessary 210 
for the interaction of mammalian SWI/SNF chromatin remodeling complexes with regulatory 211 
sequences of myogenic genes.   212 
 213 
Mutation of Brg1 sites of Cn activity prevents its interaction with myogenic gene promoters 214 
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In previous work, we showed that PKC-mediated phosphorylation of Brg1 prior to the 215 
onset of differentiation was counteracted by Cn-mediated dephosphorylation and activation of 216 
Brg1 immediately after the onset of differentiation (20). Serine amino acids targeted by 217 
PKC/Cn mapped to N- and C-terminal of the Brg1 bromodomain. Mutation of these sites to the 218 
phosphomimetic amino acid glutamate (SE) prevented myogenesis, whereas mutation to the non-219 
phosphorylatable amino acid alanine (SA) had no effect on differentiation (20). These 220 
experiments used primary myoblasts derived from Brg1-deficient mice that were reconstituted 221 
with wildtype (WT)-, SA-, or SE-Brg1. We performed ChIP experiments in differentiating cells 222 
and showed that Cn and Brg1 are bound to myogenic promoters in myoblasts expressing WT-223 
Brg1 (Fig. 8A, B). The SE-Brg1 mutant was incapable of binding; the repressive 224 
phosphorylation of Brg1 caused by PKC is mimicked by the glutamate substitutions, rendering 225 
Cn incapable of activating Brg1. As expected, the SA-Brg1 mutant, which cannot be 226 
phosphorylated at the relevant PKC target amino acids, bound Brg1 and Cn to myogenic 227 
regulatory sequences (Fig. 8A, B). These results are consistent with those obtained with the Cn 228 
inhibitor, and they reinforce the conclusion that Cn function regulates Brg1 binding to chromatin 229 
at myogenic gene regulatory sequences. 230 
 231 
Cn inhibition does not impact the ability of Cn and Brg1 to interact 232 
We previously showed that Cn and Brg1 can be co-immunoprecipitated from cell lysate 233 
of differentiating cells (20). Inhibition of Cn function with FK506 had no impact on the ability of 234 
these proteins to be isolated in complex with each other (Fig. 9A). As a complement to this 235 
experiment, we looked at the interaction of Cn with Brg1 in proliferating and differentiating 236 
myoblasts (Fig. 9B) and in differentiating myoblasts expressing WT-, SA-, or SE-Brg1 (Fig. 237 
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9C). Cn interacted with Brg1 only in the differentiating myoblasts. Cn could interact with WT-, 238 
SA-, and SE-Brg1 mutants (Fig. 9C), despite the observation that SE-Brg1 was not competent 239 
for interaction with chromatin. Brg1 can also form a complex with MyoD during differentiation 240 
(15, 65). We examined if the Brg1 mutants could interact with MyoD and determined that the 241 
Brg1-MyoD interaction was not disrupted by the Brg1 mutations (Fig. 9C). As an additional 242 
negative control for our co-IP experiments, we used conditional Brg1 KO cells. When Brg1 243 
expression was depleted by Cre recombinase, the Brg1-Cn interaction was not observed, 244 
confirming the specificity of the pulldown (Fig. 9D). These results indicate that inhibition of Cn 245 
function and mutation of the sites of Cn activity on Brg1 do not affect the interaction that exists 246 
between these regulatory proteins. The continued existence of Brg1 protein in the presence of the 247 
Cn inhibitor and when Cn-targeted residues are mutated to alanine or glutamine suggests that the 248 
lack of appropriate phosphorylation or dephosphorylation does not have significant impact on the 249 
steady-state levels of Brg1 and therefore is unlikely to be a major regulator of protein stability. 250 
 251 
Inhibition of calcineurin blocks MyoD binding to regulatory sequences of myogenic genes 252 
Recruitment of MyoD to myogenic promoters prior to the onset of differentiation can be 253 
accomplished by different mechanisms, including gene-specific mechanisms (24, 65, 66). Our 254 
RNA-seq data and our prior RT-qPCR analysis (20) showed that MyoD expression was not 255 
changed by FK506 treatment. The continued presence of MyoD on myogenic promoters after the 256 
onset of differentiation requires the Brg1 ATPase (15, 65). We would therefore predict that the 257 
inhibition of Cn would affect the interaction of MyoD with myogenic gene regulatory sequences. 258 
We assessed MyoD enrichment at the regulatory sequences of tested genes by ChIP. As shown in 259 
Fig. 10, we observed enhanced enrichment of MyoD at all analyzed gene promoters in 260 
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 14 
differentiated cells compared to enrichment prior to or at the onset of differentiation. 261 
Recruitment of MyoD at these regulatory sequences was attenuated by the Cn inhibitor. These 262 
results support the conclusion that Cn is necessary for the stable binding of MyoD to the 263 
myogenic gene regulatory sequences during differentiation. 264 
 265 
shRNA-mediated knockdown of Cn impaired myoblast differentiation, affected gene 266 
expression and blocked binding of Cn, Brg1 and MyoD to myogenic regulatory sequences. 267 
The combination of an inhibitor Cn activity and mutation of residues on Brg1 that are Cn 268 
substrates gave consistent results with regard to the mechanism of Cn function during myogenic 269 
gene expression. Nevertheless, to provide additional confirmation, we reduced overall Cn levels 270 
by shRNA-mediated targeting and repeated all of the experiments. Two distinct shRNAs specific 271 
for the catalytic subunit of calcineurin A (Ppp3ca) were used. ShCn-1 targets the 3’UTR and the 272 
shCn-2 targets the coding sequence. Cells infected with lentivirus expressing either of the 273 
shRNAs targeting Cn or the control shRNA (shCtrl) were selected for puromycin and then 274 
evaluated for Cn expression and cells differentiation (Fig. 11A). The shCtrl had no effect on Cn 275 
expression and differentiation. Both shCn-1 and shCn-2 had significant reduction of Cn protein 276 
and mRNA expression compared to the control. Myoblast differentiation was evaluated by 277 
myosin heavy chain staining (Fig. 11B); we observed significant reduction in myotube formation 278 
in 72h differentiated cells. Consistent with the reduction of Cn protein level and lack of 279 
differentiation, mRNA expression of myogenic genes (cluster 2 genes from RNA-seq analysis) 280 
Myog, Ckm, Cav3, Myh4, Tnnt3, Acta1 and Mymk were significantly reduced in the Cn 281 
knockdown cells (Fig. 11C). A representative gene from clusters 1, 3, and 4 (Smahd1 (cluster1), 282 
Cxcl1 (cluster 3) and Larp1b (cluster 4)) were also affected by knocking down Cn (Fig. 11D). 283 
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 15 
Next, we analyzed recruitment of Cn, Brg1 and MyoD to four of the previously 284 
interrogated myogenic regulatory sequences (Fig. 12A-C). As expected, all three proteins were 285 
bound to the indicated regulatory sequences in the shCtrl differentiated cells. Cn binding to the 286 
regulatory sequences in the Cn knockdown cells was impaired (Fig. 12A). Brg1 and MyoD 287 
binding (Fig. 12B, C) were also impaired in the Cn knockdown cells, which demonstrates that 288 
the reduction in Cn blocked the interaction of these protein with the myogenic regulatory 289 
sequences. These results further support the conclusion that Cn promotes myoblast 290 
differentiation by binding to myogenic regulatory sequences, facilitating binding of the Brg1 291 
chromatin remodeling enzyme and the stable binding of MyoD and contributing to the activation 292 
of the myogenic gene expression program.   293 
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DISCUSSION 294 
Cn broadly contributes to the activation of the myogenic gene expression program during 295 
differentiation 296 
The data presented here demonstrate that Cn plays a general role in regulating myogenic 297 
gene expression during the myoblast differentiation. Its mechanism of action is via binding and 298 
dephosphorylation of the Brg1 ATPase of the mammalian SWI/SNF chromatin remodeling 299 
enzyme, which regulates the ability of Brg1 and other SWI/SNF enzyme subunits to stably 300 
associate with myogenic promoters during differentiation. We and others have previously 301 
demonstrated that Brg1-based SWI/SNF enzymes remodel chromatin at myogenic regulatory 302 
sequences in differentiating cells (15, 16, 65). Failure of Cn to promote association of Brg1 and 303 
associated mSWI/SNF enzyme subunits prevents the required enzymatic remodeling of promoter 304 
chromatin structure and subsequent gene activation during differentiation.  305 
The consistent observation of Cn binding to each of the myogenic promoters assayed 306 
suggests that Cn is directly required for the activation of each target gene. The alternative 307 
hypothesis was that Cn required indirectly via a requirement for activation of myogenin, which is 308 
required for activation of myogenic gene products that promote terminal differentiation (67, 68). 309 
In prior work examining other cofactors of myogenic gene expression, we determined that the 310 
SWI/SNF chromatin remodeling enzyme was required for the expression of both myogenin and 311 
subsequent gene expression (51). These new results spatially link Cn and SWI/SNF enzyme 312 
binding to myogenic promoters, which is consistent with Cn function being required for 313 
SWI/SNF enzyme function. In contrast, the Prmt5 arginine methyltransferase is required for 314 
myogenin activation, but ectopic expression of myogenin promoted myogenic gene expression 315 
and differentiation even in the absence of Prmt5 (69), indicating that the requirement for Prmt5 316 
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in later stages of the myogenic gene expression cascade was indirect. It is important to note, 317 
however, that direct evidence that Cn-mediated dephosphorylation of Brg1 must occur while 318 
bound to promoters is lacking. Future examination of Cn and PKC1 binding and function at 319 
myogenic regulatory sequences will enable elucidation of mechanistic details about the timing, 320 
dynamics, and spatial requirements for Brg1 phosphorylation and dephosphorylation.   321 
The promoter binding capability of Cn is a novel function that is poorly understood.  322 
There is no evidence that Cn contains a recognized DNA binding domain, raising the possibility 323 
that it binds chromatin indirectly.  The absence of Cn binding in the presence of the Cn inhibitor 324 
suggests the possibility of auto-dephosphorylation as a necessary pre-requisite. However, prior 325 
studies indicate that autodephosphorylation is slow and that phosphorylated Cn is more 326 
efficiently dephosphorylated by protein phosphatase IIa (70). An alternative hypothesis is that 327 
Cn inhibition alters the structure or function of a Cn binding partner, which directly or indirectly 328 
results in loss of association with chromatin.  329 
 330 
Regulation of SWI/SNF enzyme by subunit composition and by phosphorylation state  331 
The diversity of mammalian SWI/SNF enzyme complex formation is due in part to the 332 
existence of several subunits that exclusively or predominantly associate with subsets of enzyme 333 
complexes (12, 19). The Baf250A subunit exists in a subset of SWI/SNF complexes known as a 334 
SWI/SNF-A or BAF, which contains several unique subunits not found in the other major 335 
subfamily of SWI/SNF complexes, referred to as SWI/SNF-B or PBAF complexes (71). The 336 
presence of Baf250A at each of the promoters assays suggests that the A/BAF complex may be 337 
the functionally relevant enzyme to promote skeletal muscle differentiation. 338 
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The literature on which specific enzyme complex(es) act at muscle-specific promoters is 339 
limited. Brg1 has been identified at many myogenic promoters. Interference with Brg1 function 340 
through expression of a dominant negative enzyme, injection of specific antibodies, or via 341 
knockdown blocks myogenic gene expression and differentiation (15, 16, 24, 65, 72), but these 342 
data do not distinguish between different types of SWI/SNF enzymes. The Brm ATPase binds to 343 
the myogenin promoter in isolated mouse myofibers, but not in isolated satellite cells (73). 344 
However, knockdown of Brm in cultured myoblasts had limited effect on differentiation-specific 345 
gene expression while instead affecting cell cycle withdrawal (72). Those data indicate that 346 
A/BAF complex function is a necessary pre-requisite for myoblast differentiation. In mouse 347 
heart development, the B/PBAF specific subunits BAF200 and BAF180 are required (74-76), but 348 
Baf250A knockout in mouse neural crest leads to embryonic death due to defective cardiac 349 
development (77). Despite the intriguing ramifications of thousands of different potential 350 
SWI/SNF enzyme compositions, comparison of complexes formed by A/BAF and B/PBAF-351 
specific subunits in the same cell type showed that genomic binding sites and transcriptionally 352 
responsive genes largely overlapped, leading to the conclusion that the regulation of gene 353 
expression by SWI/SNF enzymes is due to the combined effect of multiple SWI/SNF enzymes 354 
(78). Muscle development and differentiation may similarly rely on multiple SWI/SNF enzyme 355 
assemblies and may not be attributable to one specific enzyme complex. 356 
Regulation of SWI/SNF chromatin remodeling enzyme activity, via control of the 357 
phosphorylation state of different proteins within the enzyme complex, is an emerging 358 
complexity that adds to the alarming complexity posed by the thousands of potential 359 
combinatorial assemblies of the enzyme complex from its component subunit proteins (12, 19) . 360 
Nevertheless, the evidence for this additional layer of regulation is clear. Amino acids N- and C-361 
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terminal to the Brg1 bromodomain are phosphorylated by PKC1 in proliferating myoblasts and 362 
dephosphorylated by Cn after the onset of differentiation signaling. Failure to remove the 363 
phosphorylation prevents remodeling enzyme function and differentiation, while mutation of 364 
these amino acids to prevent phosphorylation permits function even in the presence of a Cn 365 
inhibitor (20). Here we demonstrate the generality of the requirement for Cn-mediated 366 
facilitation of Brg1 function. The PKC1/Cn axis is joined by p38 kinase-mediated 367 
phosphorylation of the Baf60c subunit that permits assembly of the SWI/SNF enzyme complex 368 
on myogenic promoters (24). Most of the SWI/SNF subunits have been characterized as 369 
phosphoproteins (79), suggesting that regulation of activity in response to differentiation 370 
signaling may be influenced by other kinases and phosphatases as well.  371 
The consequences of phosphorylation and dephosphorylation of the PKC1/Cn- targeted 372 
amino acids on Brg1 structure remain to be determined. The fact that Brg1 protein remains 373 
present when the relevant amino acids are mutated or when exposed to Cn inhibitor indicates that 374 
the phosphorylation state of these amino acids does not render the Brg1 protein unstable. The 375 
failure of other SWI/SNF subunits to remain associated with myogenic gene chromatin suggests 376 
that the phosphorylation state may control Brg1 protein conformation, interactions with 377 
chromatin, interactions with other SWI/SNF enzyme subunits, and/or interactions with other 378 
cofactors that contribute to enzyme complex stability or chromatin binding. Additional 379 
characterization will improve our understanding of Brg1 and SWI/SNF chromatin remodeling 380 
enzyme function in differentiation and may also inform studies on the role of Brg1 in 381 
oncogenesis, where Brg1 can be either mutated or overexpressed without mutation in different 382 
types of cancer (80, 81). 383 
  384 
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MATERIALS AND METHODS 385 
Antibodies. Rabbit antisera to Brg1 and MyoD were previously described (65, 82). Pan-386 
Calcineurin A (#2614), Baf170 (#12769), Baf250A (#12354), and TBP (#8515) antibodies were 387 
from Cell Signaling Technologies (Danvers, MA). GAPDH antibody (#G9295) was from Sigma-388 
Aldrich (St. Louis, MO). MF20 antibody was from the Developmental Studies Hybridoma Bank 389 
(Iowa City, IA). Brg1 antibody (G-7, #sc-17796) was from Santa Cruz Biotechnologies (Santa 390 
Cruz, CA) and was used for western blotting and immunoprecipitation experiments.  391 
Cell culture. C2C12 and HEK293T cells were purchased from ATCC (Manassas, VA) and were  392 
maintained at subconfluent densities in Dulbecco’s modified Eagle's medium (DMEM) 393 
supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified incubator at 37°C 394 
in 5% CO2. For differentiation, C2C12 cells at  80% confluency were switched to DMEM 395 
medium supplemented with 2% horse serum and 2 g/ml of bovine insulin (Sigma-Aldrich). 396 
FK506 (Cayman Chemical, Ann Arbor, MI) was added to the culture 24h before initiating 397 
differentiation and maintained in the differentiation media at 2M. Media containing FK506 398 
was changed every day.  399 
Mouse satellite cells were isolated from leg muscles of 3- to 6-week old Brg1 conditional 400 
mice using Percoll sedimentation followed by differential plating as described previously (20). 401 
Mice were housed in the animal care facility at the University of Massachusetts Medical 402 
School and used in accordance with a protocol approved by the Institutional Animal Care and 403 
Use Committee. Brg1 depleted primary myoblasts expressing wild type (WT) Brg1 or Brg1 404 
mutated at sites of PKC1/Cn activity were generated as described (20). Primary myoblasts were 405 
grown and differentiated as described (20) on plates coated overnight in 0.02% collagen 406 
(Advanced BioMatrix, San Diego, CA).  407 
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shRNA gene knockdown and lentivirus gene transfer.  408 
Calcineurin A, isoform A-targeting shRNA in pLKO.1 vector was obtained from Sigma Aldrich 409 
(SHCLNG-NM_008913). shRNA sequences were as follows: shRNA 1: 410 
CCGGGCCAGGAATTGGATTCAGTTTCTCGAGAAACTGAATCCAATTCCTGGCTTTTT411 
G (TRCN0000081058); shRNA2: 412 
CCGGCGCCAACCTTAACTCCATCAACTCGAGTTGATGGAGTTAAGGTTGGCGTTTTT413 
G (TRCN0000081060); The scrambled shRNA control sequence was: 414 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG, generated by 415 
Sarbassov et al., (83) and was obtained from Addgene, Cambridge, MA (plasmid # 1864). The 416 
shRNA lentiviral constructs were co-transfected with pLP1, pLP2 and pVSVG packaging 417 
vectors (Invitrogen, Carlsbad, CA) into HEK293T cells with Lipofectamine 2000 reagent 418 
(Invitrogen). The viral supernatant was harvested after 48h incubation and filtered through a 419 
0.45 μm syringe filter. To infect C2C12 cells, 2.7 × 105 cells were incubated with 5 ml of the 420 
filtered viral supernatant supplemented with 8 μg ml−1 of polybrene (Sigma-Aldrich) for 24 h. 421 
The transduced cells were subsequently selected in media containing 2 μg/ml puromycin 422 
(Invitrogen) for 4 days. 423 
RNA-Seq and Data Analysis. Total RNA from C2C12 cells treated with FK506 or with DMSO 424 
was isolated from proliferating and differentiating cultures (time 0, 24h and 72h) with TRIzol, 425 
and libraries were constructed as described (84). Five replicates were performed for each sample 426 
except for the 72h sample treated with DMSO, which had only four replicates. The libraries were 427 
sequenced using the Illumina HiSeq 1500 and the resulting reads were mapped onto the 428 
reference mouse genome (GRCm38) by HISAT2 (ver. 2.2.6) (85). Read counting per gene was 429 
performed with HTseq (ver. 0.6.1) (86) such that duplicates in unique molecular identifiers were 430 
discarded. After converting UMI counts to transcript counts as described (87), differentially 431 
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expressed genes, (those with adjusted p-value 0.1) were extracted by the R library DESeq2 432 
(version 1.10.1) (88). The differentially expressed genes and cluster analyses are listed in 433 
Supplementary Tables S1 and S2. Gene ontology (GO) term identification was performed on 434 
metascape: http://metascape.org. Cluster gene analysis was performed using clusterProfiler (ver. 435 
3/10.0), a multi-purpose, open-source tool to identify and compare functional relationships 436 
between genes (50). RNA-seq data were deposited at the Gene Expression Omnibus (GEO) 437 
database under accession number GSE125914. The reviewer access token is krexscswllodxwn. 438 
Motif analysis was performed using HOMER motif discovery software as described (89). The 439 
promoters of genes that were differentially expressed genes upon FK506 treatment were 440 
analyzed for the enrichment of known motifs. For each gene, we looked for motif enrichment up 441 
to 1 kb upstream of the TSS.  442 
RT-qPCR gene expression analysis. RNA was extracted using TRIzol Reagent (Invitrogen) 443 
and the yield determined by measuring OD260. 1µg of total RNA was subjected to reverse 444 
transcription with a QuantiTect Reverse Transcription Kit (Qiagen, Germantown, MD). The 445 
resulting cDNA was used for quantitative PCR using a Fast SYBR green master mix (Applied 446 
Biosystems, Foster City, CA). Amplification reactions were performed in duplicate in 10 μl final 447 
volume that included the following: 25 ng of template, 0.3 μM primers, 2× SYBR Green Master 448 
Mix. Reactions were processed in QuantStudio3 (Applied Biosystems) using following primers: 449 
Acta1 forward 5’-cttcctttatcggtatggagtctgcgg-3’, reverse 5’-ggggggcgatgatcttcatg-3’; Cav3 450 
forward 5’- tcaatgaggacattgtgaaggtaga-3’, reverse 5’-cagtgtagacaacaggcggt-3’; Ckm forward 5’-451 
ctgtccgtggaagctctcaacagc-3’, reverse 5’-ttttgttgtcgttgtgccagatgcc-3’; Cxcl1: forward 5’-452 
accgagtcatagccacactc-3’, reverse 5’-ctccgttacttggggacacc-3’; Eef1A1 forward 5’-453 
ggcttcactgctcaggtgattatc-3’, reverse 5’-acacatgggcttgccagggac-3’; Id1: forward 5’-454 
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aggtgaggcggcatgtgttccag-3’, reverse 5’-accctctacccactggaccg-3’; Larp1b: forward 5’-455 
cagtcaagcagccagaggaa-3; reverse 5’-ctctcccgtctccaacttcg-3’;  Myh4 forward 5’-456 
ggctttgagatctttgacttcaacacc-3’, reverse 5’-gagaagatgcccatcggcttctcg-3’; Mymk forward 5’-457 
gagaagatgcccatcggcttctcg-3’, reverse 5’-gtcggccagtgccatcaggga-3’; Myog forward 5’-458 
gtcccaacccaggagatcatttgctc-3’, reverse 5’-cccacttaaaagccccctgctac-3’; Pix3r1: forward 5’-459 
tggatttcctgggaagtacgg-3’, reverse 5’-aagccgaagatccgtaaggc-3’; Ppp3ca: forward 5’-460 
ggtcggggtgtgcagtc-3’, reverse 5’-atggaacggctttcaccacc-3’; Rrp12: forward: 5’-461 
aagccgaagatccgtaaggc-3’. reverse: 5’-aggggccttttcaccaaaca-3’; Samhd1: forward 5’-462 
gagcagctcattcgggtgta-3’; reverse 5’-tgtcaccatcctgtggct-3’; Tnnt3 forward 5’-463 
tgacaagctgagggacaagg-3’, reverse 5’-tgcttctgggcttggtcaat-3’. ΔCt for each gene was calculated 464 
and represents the difference between the Ct value for the gene of interest and that of the 465 
reference gene, Eef1A1. Fold-changes were calculated using the 2
−ΔΔC
t method (90).  466 
Chromatin immunoprecipitation (ChIP) assay. Chromatin immunoprecipitation assays were 467 
performed as previously described (20, 91) with some modifications. Briefly, cells (4  106) 468 
were cross-linked with 1% formaldehyde (Ted Pella Inc., Redding, CA) for 10 minutes at room 469 
temperature. After quenching the formaldehyde with 125 mM glycine for 5 minutes, fixed cells 470 
were washed twice with PBS supplemented with protease inhibitor cocktail and lysed with 1 ml 471 
buffer A (10 mM Tris HCl, pH 7.5, 10 mM NaCl, 0.5% NP40, 0.5 M DTT and protease 472 
inhibitors) by incubation on ice for 10 minutes. The nuclei were pelleted, washed with 1 ml of 473 
buffer B (20 mM Tris HCl, pH 8.1, 15 mM NaCl, 60 mM KCl, 1 mM CaCl2, 0.5 M DTT) and 474 
incubated for 30 minutes at 37°C in the presence of 1000 gel units of micrococcal nuclease 475 
(#M0247S, NEB, Ipswich, MA) in 300 l volume of buffer B. The reaction was stopped by 476 
adding 15 l of 0.5 M EDTA. Nuclei were pelleted and resuspended in 300 l of ChIP buffer 477 
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(100 mM Tris HCl, pH 8.1, 20 mM EDTA, 200 mM NaCl, 0.2 % sodium deoxycholate, 2% 478 
Triton X 100 and protease inhibitors), sonicated for 10 minutes (medium intensity, 30 sec-on/ 30 479 
sec-off) in a Bioruptor UCD-200 (Diagenode, Denville, NJ) and centrifuged at 21,000 × g for 5 480 
minutes. The fragmented chromatin was between 200–500 bp as analyzed on agarose gels. 481 
Chromatin concentration was measured using Qubit 3 (Invitrogen). After preclearing with 482 
protein A agarose, chromatin (2-4 µg) was subjected to immunoprecipitation with specific 483 
antibodies listed above, or with anti-IgG as negative control at 4°C overnight, and 484 
immunocomplexes were recovered by incubation with protein A agarose magnetic beads 485 
(Invitrogen). Sequential washes of 5 minutes each were performed with buffers A-D (Buffer A: 486 
50 mM Tris pH 8.1, 10 mM EDTA, 100 mM NaCl, 1% Triton X 100, 0.1% sodium 487 
deoxycholate; Buffer B: 50 mM Tris pH 8.1, 2 mM EDTA, 500 NaCl, 1% Triton-X100, 0.1% 488 
sodium deoxycholate; Buffer C: 10 mM Tris pH 8.1, 1 mM EDTA, 0.25 M LiCl2; 1% NP-40, 489 
1% sodium deoxycholate; Buffer D: 10 mM Tris pH 8.1, 1 mM EDTA), immune complexes 490 
were eluted in 100 µl of elution buffer (0.1 M NaHCO3, 1% SDS) for 30 minutes at 65°C, 491 
incubated with 1 l of RNnase A (0.5 mg/ml) for 30 minutes at 37C, and reverse cross-linked 492 
by adding 6 l of 5M NaCl and 1 l of proteinase K (1 mg/ml) overnight at 65°C. DNA was 493 
purified using the ChIP DNA clean & concentrator kit (Zymo Research, Irvine, CA). Bound 494 
DNA fragments were analyzed by quantitative PCR using the SYBR Green Master Mix. 495 
Quantification was performed using the fold enrichment method (2
-(Ct sample – Ct IgG)
) and shown as 496 
relative to a control region, the promoter for the Pdx1 gene. Primer sequences used were: Acta1 497 
forward 5’-tgttgctgcccttcccaagccatattt-3’, reverse 5’-gcagacagctggggatactctccatat-3’; Cav3 498 
forward 5’-cctaggtgtctcagtccagtta-3’, reverse 5’-ctgccacgtagatcttggaaat-3’; Ckm forward 5’-499 
gacacccgagatgcctggtt-3’, reverse 5’-gatccaccagggacagggtt-3’; Myh4 forward 5’-500 
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cacccaagccgggagaaacagcc-3’, reverse 5’-gaggaaggacaggacagaggcacc-3’; Mymk forward 5’-501 
ctgacagcagggttagggct-3’, reverse 5’-tgatgtgtaccctttctcccc-3’; Myog forward 5’-502 
acaccaactgctgggtgcca-3’, reverse 5’-gaatcacatgtaatccactgg-3’; Tnnt3 forward 5’-503 
gcagctgacacctttctggaac-3’, reverse 5’-attggccagcagatgggtgg-3’. The silent gene promoter Pdx1 504 
was used as a negative control, as shown previously (62); forward 5’-505 
gaagtcctccggacatctccccatacgaag-3’, reverse 5’-ggatttcatccacgggaaagggagctggac-3’. Primer 506 
positions and localization of E-boxes for each regulatory sequence (53-61) are shown 507 
schematically in Fig. 6A.  508 
Immunoprecipitation. 100 mm dishes of 24h differentiated C2C12 cells treated with FK506 or 509 
with DMSO or 100 mm dishes of primary myoblasts expressing wildtype or Brg1 mutants were 510 
washed with ice-cold PBS twice and lysed in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 511 
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1mM CaCl2 and supplemented 512 
with complete protease inhibitors). Lysates were cleared by centrifugation and precleared with 513 
PureProteome Protein A magnetic beads (Millipore) for 2 hours at 4C. Next, cell extract was 514 
incubated with 10 μl of Pan-Calcineurin A antibody (Cell Signaling Technologies) or 10 μl of 515 
Brg1 antisera overnight at 4°C, followed by incubation with 100 l with PureProteome Protein A 516 
mix magnetic beads. After extensive washing of beads with washing buffer (24 mM Tris-HCl, 517 
pH 7.5, 300 mM NaCl, 0.5% NP-40 and 1mM CaCl2), precipitated proteins were eluted in 518 
Laemmli buffer and detected by western blot analysis using chemiluminescent detection. 519 
Immunofluorescence. Cells grown on coverslips were fixed with 3% paraformaldehyde, 520 
permeabilized with 0.5% Triton X-100, and blocked with 1% BSA solution in PBS. Primary and 521 
secondary antibodies were diluted in 1% blocking solution. The primary antibody against myosin 522 
heavy chain, mAb MF20 was used at a dilution of 1:100. Goat ani-mouse secondary antibody 523 
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conjugated with Alexa 488 (Jackson Labs, West Grove, PA) were applied for 1 h at room 524 
temperature. DAPI staining was used to visualize nuclei. The samples were mounted with 525 
ProLong Gold antifade reagent (Life Technologies) and observed with inverted fluorescence 526 
microscopy (Leica DMI6000). Leica LAS AF Lite software was used for recording and image 527 
processing. 528 
Subcellular fractionation. Cell fractionation was performed as described (92). Briefly, cell 529 
pellets were resuspended in hypotonic buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM 530 
KCl, 0.5 mM DTT supplemented with protease inhibitor cocktail). Cell suspension was 531 
centrifuged, and the supernatant discarded. Intact pelleted cells were resuspended in buffer A and 532 
pushed through a 26G needle to disrupt the cell membrane. Disrupted cell suspension was 533 
centrifuged at 10,000 × g for 20 minutes and the supernatant was saved as the cytosolic fraction. 534 
Pelleted nuclei were resuspended in buffer C (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.42 M 535 
NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM DTT supplemented with complete protease 536 
inhibitor cocktail) and disrupted by pushing 10 times through a 26G needle. The nuclear 537 
suspension was centrifuged at 20,000 × g for 5 min and the supernatant was saved as the nuclear 538 
extract. Chromatin isolation was performed as described previously (21). Cells were resuspended 539 
in cytoskeleton buffer (CSK: 10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM 540 
MgCl2, 1 mM EGTA, 1 mM DTT, and 0.5% (v/v) Triton X-100 and complete protease inhibitor 541 
cocktail). The cytosolic fraction was separated from soluble proteins by centrifugation and the 542 
pellet was resuspended in CSK buffer. Chromatin was solubilized by DNase I digestion (New 543 
England Biolabs) in CSK buffer for 15 min at 37 °C. 0.25 M (NH4)2SO4 was added, and the 544 
samples were incubated for 5 min at 4 °C, centrifuged at 5,000 × g for 3 min and supernatant was 545 
saved as a soluble chromatin fraction. 546 
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Statistical analysis. All quantitative ChIP and RT-qPCR data are shown as mean +/- the 547 
standard deviation (SD) of at least three (n=3) biological replicates for each experiment. 548 
Statistical analysis was performed using GraphPad Prism Student’s t- test (GraphPad Software 549 
Inc.). For all analyses, a P-value of less than 0.05 was considered to be statistically significant.  550 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 28 
ACKNOWLEDGEMENTS 551 
This work was supported by NIH grant GM56244 to ANI, by a Faculty Diversity Scholars 552 
Program award from the University of Massachusetts Medical School to TP-B, and by 553 
MEXT/JSPS KAKENHI (JP25116010, JP17H03608, JP17K19356, JP18H04802 and 554 
JP18H05527) and JST CREST JPMJCR16G1 to YO. We also thank the Advanced 555 
Computational Scientific Program of the Research Institute for Information Technology, Kyushu 556 
University, and the National Institute of Genetics for providing high-performance computing 557 
resources.  558 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 29 
REFERENCES 559 
1. Hernandez-Hernandez JM, Garcia-Gonzalez EG, Brun CE, Rudnicki MA. 2017. The 560 
myogenic regulatory factors, determinants of muscle development, cell identity and 561 
regeneration. Semin Cell Dev Biol 72:10-18. 562 
2. Harada A, Ohkawa Y, Imbalzano AN. 2017. Temporal regulation of chromatin during 563 
myoblast differentiation. Semin Cell Dev Biol 72:77-86. 564 
3. Sartorelli V, Puri PL. 2018. Shaping Gene Expression by Landscaping Chromatin 565 
Architecture: Lessons from a Master. Mol Cell 71:375-388. 566 
4. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, 567 
Goff SP, Yaniv M, Workman JL, Crabtree GR. 1996. Purification and biochemical 568 
heterogeneity of the mammalian SWI-SNF complex. EMBO J 15:5370-82. 569 
5. Imbalzano AN, Kwon H, Green MR, Kingston RE. 1994. Facilitated binding of TATA-570 
binding protein to nucleosomal DNA. Nature 370:481-5. 571 
6. Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR. 1994. Nucleosome 572 
disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 573 
370:477-81. 574 
7. Seeber A, Hauer M, Gasser SM. 2013. Nucleosome remodelers in double-strand break 575 
repair. Curr Opin Genet Dev 23:174-84. 576 
8. Clapier CR, Cairns BR. 2014. Chromatin remodeling complexes, In Fundamentals of 577 
Chromatin, vol 9781461486244, Springer. 578 
9. Lorch Y, Kornberg RD. 2015. Chromatin-remodeling and the initiation of transcription. 579 
Q Rev Biophys 48:465-70. 580 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 30 
10. Clapier CR, Iwasa J, Cairns BR, Peterson CL. 2017. Mechanisms of action and regulation 581 
of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol 18:407-582 
422. 583 
11. Romero OA, Sanchez-Cespedes M. 2014. The SWI/SNF genetic blockade: effects in cell 584 
differentiation, cancer and developmental diseases. Oncogene 33:2681-9. 585 
12. Wu JI. 2012. Diverse functions of ATP-dependent chromatin remodeling complexes in 586 
development and cancer. Acta Biochim Biophys Sin (Shanghai) 44:54-69. 587 
13. Ho L, Crabtree GR. 2010. Chromatin remodelling during development. Nature 463:474-588 
84. 589 
14. de la Serna IL, Ohkawa Y, Imbalzano AN. 2006. Chromatin remodelling in mammalian 590 
differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 7:461-73. 591 
15. Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL. 2004. p38 pathway 592 
targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet 593 
36:738-43. 594 
16. de la Serna IL, Carlson KA, Imbalzano AN. 2001. Mammalian SWI/SNF complexes 595 
promote MyoD-mediated muscle differentiation. Nat Genet 27:187-90. 596 
17. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR. 1993. BRG1 contains 597 
a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and 598 
transcription. Nature 366:170-4. 599 
18. Muchardt C, Yaniv M. 1993. A human homologue of Saccharomyces cerevisiae 600 
SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the 601 
glucocorticoid receptor. EMBO J 12:4279-90. 602 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 31 
19. Hargreaves DC, Crabtree GR. 2011. ATP-dependent chromatin remodeling: genetics, 603 
genomics and mechanisms. Cell Res 21:396-420. 604 
20. Nasipak BT, Padilla-Benavides T, Green KM, Leszyk JD, Mao W, Konda S, Sif S, 605 
Shaffer SA, Ohkawa Y, Imbalzano AN. 2015. Opposing calcium-dependent signalling 606 
pathways control skeletal muscle differentiation by regulating a chromatin remodelling 607 
enzyme. Nat Commun 6:7441. 608 
21. Padilla-Benavides T, Nasipak BT, Paskavitz AL, Haokip DT, Schnabl JM, Nickerson JA, 609 
Imbalzano AN. 2017. Casein kinase 2-mediated phosphorylation of Brahma-related gene 610 
1 controls myoblast proliferation and contributes to SWI/SNF complex composition. J 611 
Biol Chem 292:18592-18607. 612 
22. Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, 613 
Pike JW, Yuan M, Ahlquist P, Xu W. 2016. CARM1 Methylates Chromatin Remodeling 614 
Factor BAF155 to Enhance Tumor Progression and Metastasis. Cancer Cell 30:179-180. 615 
23. Cui H, Schlesinger J, Schoenhals S, Tonjes M, Dunkel I, Meierhofer D, Cano E, Schulz 616 
K, Berger MF, Haack T, Abdelilah-Seyfried S, Bulyk ML, Sauer S, Sperling SR. 2016. 617 
Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy 618 
through releasing HEY repressors from DNA. Nucleic Acids Res 44:2538-53. 619 
24. Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A, Coutinho P, 620 
Saccone V, Consalvi S, Williams R, Wang K, Wu Z, Baranovskaya S, Miller A, Dilworth 621 
FJ, Puri PL. 2012. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based 622 
SWI/SNF chromatin-remodelling complex. EMBO J 31:301-16. 623 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 32 
25. Stewart AA, Ingebritsen TS, Manalan A, Klee CB, Cohen P. 1982. Discovery of a Ca2+- 624 
and calmodulin-dependent protein phosphatase: probable identity with calcineurin (CaM-625 
BP80). FEBS Lett 137:80-4. 626 
26. Rusnak F, Mertz P. 2000. Calcineurin: form and function. Physiol Rev 80:1483-521. 627 
27. Manalan AS, Krinks MH, Klee CB. 1984. Calcineurin: a member of a family of 628 
calmodulin-stimulated protein phosphatases. Proc Soc Exp Biol Med 177:12-6. 629 
28. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. 1991. 630 
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 631 
complexes. Cell 66:807-15. 632 
29. Shaw KT, Ho AM, Raghavan A, Kim J, Jain J, Park J, Sharma S, Rao A, Hogan PG. 633 
1995. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor 634 
NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A 92:11205-9. 635 
30. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. 1991. Nuclear association of a T-cell 636 
transcription factor blocked by FK-506 and cyclosporin A. Nature 352:803-7. 637 
31. Ruff VA, Leach KL. 1995. Direct demonstration of NFATp dephosphorylation and 638 
nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. 639 
J Biol Chem 270:22602-7. 640 
32. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, 641 
Bassel-Duby R, Williams RS. 1998. A calcineurin-dependent transcriptional pathway 642 
controls skeletal muscle fiber type. Genes Dev 12:2499-509. 643 
33. Schiaffino S, Sandri M, Murgia M. 2007. Activity-dependent signaling pathways 644 
controlling muscle diversity and plasticity. Physiology (Bethesda) 22:269-78. 645 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 33 
34. Dunn SE, Burns JL, Michel RN. 1999. Calcineurin is required for skeletal muscle 646 
hypertrophy. J Biol Chem 274:21908-12. 647 
35. Horsley V, Friday BB, Matteson S, Kegley KM, Gephart J, Pavlath GK. 2001. 648 
Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent 649 
pathway. J Cell Biol 153:329-38. 650 
36. Ravel-Chapuis A, Belanger G, Cote J, Michel RN, Jasmin BJ. 2017. Misregulation of 651 
calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in 652 
skeletal muscle of DM1 mice. Hum Mol Genet 26:2192-2206. 653 
37. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. 1999. IGF-1 induces 654 
skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-655 
ATc1. Nature 400:581-5. 656 
38. Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, Harvey RP, Graham RM. 657 
1999. Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin 658 
signalling pathway. Nature 400:576-81. 659 
39. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. 1998. Activation and 660 
cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in 661 
skeletal muscle cells. Mol Biol Cell 9:2905-16. 662 
40. Friday BB, Horsley V, Pavlath GK. 2000. Calcineurin activity is required for the 663 
initiation of skeletal muscle differentiation. J Cell Biol 149:657-66. 664 
41. Friday BB, Mitchell PO, Kegley KM, Pavlath GK. 2003. Calcineurin initiates skeletal 665 
muscle differentiation by activating MEF2 and MyoD. Differentiation 71:217-27. 666 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 34 
42. Gunning P, Hardeman E, Wade R, Ponte P, Bains W, Blau HM, Kedes L. 1987. 667 
Differential patterns of transcript accumulation during human myogenesis. Mol Cell Biol 668 
7:4100-14. 669 
43. Bergstrom DA, Penn BH, Strand A, Perry RL, Rudnicki MA, Tapscott SJ. 2002. 670 
Promoter-specific regulation of MyoD binding and signal transduction cooperate to 671 
pattern gene expression. Mol Cell 9:587-600. 672 
44. Lin Z, Lu MH, Schultheiss T, Choi J, Holtzer S, DiLullo C, Fischman DA, Holtzer H. 673 
1994. Sequential appearance of muscle-specific proteins in myoblasts as a function of 674 
time after cell division: evidence for a conserved myoblast differentiation program in 675 
skeletal muscle. Cell Motil Cytoskeleton 29:1-19. 676 
45. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. 677 
Nature 423:337-42. 678 
46. Wu H, Peisley A, Graef IA, Crabtree GR. 2007. NFAT signaling and the invention of 679 
vertebrates. Trends Cell Biol 17:251-60. 680 
47. Cheng M, Nguyen MH, Fantuzzi G, Koh TJ. 2008. Endogenous interferon-gamma is 681 
required for efficient skeletal muscle regeneration. Am J Physiol Cell Physiol 682 
294:C1183-91. 683 
48. Jesse TL, LaChance R, Iademarco MF, Dean DC. 1998. Interferon regulatory factor-2 is 684 
a transcriptional activator in muscle where It regulates expression of vascular cell 685 
adhesion molecule-1. J Cell Biol 140:1265-76. 686 
49. Deng S, Azevedo M, Baylies M. 2017. Acting on identity: Myoblast fusion and the 687 
formation of the syncytial muscle fiber. Semin Cell Dev Biol 72:45-55. 688 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 35 
50. Yu G, Wang LG, Han Y, He QY. 2012. clusterProfiler: an R package for comparing 689 
biological themes among gene clusters. OMICS 16:284-7. 690 
51. Ohkawa Y, Marfella CG, Imbalzano AN. 2006. Skeletal muscle specification by 691 
myogenin and Mef2D via the SWI/SNF ATPase Brg1. EMBO J 25:490-501. 692 
52. Ohkawa Y, Yoshimura S, Higashi C, Marfella CG, Dacwag CS, Tachibana T, Imbalzano 693 
AN. 2007. Myogenin and the SWI/SNF ATPase Brg1 maintain myogenic gene 694 
expression at different stages of skeletal myogenesis. J Biol Chem 282:6564-70. 695 
53. Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, Hauschka SD, Weintraub H. 696 
1989. MyoD is a sequence-specific DNA binding protein requiring a region of myc 697 
homology to bind to the muscle creatine kinase enhancer. Cell 58:823-31. 698 
54. Luo W, Li E, Nie Q, Zhang X. 2015. Myomaker, Regulated by MYOD, MYOG and 699 
miR-140-3p, Promotes Chicken Myoblast Fusion. Int J Mol Sci 16:26186-201. 700 
55. Biederer CH, Ries SJ, Moser M, Florio M, Israel MA, McCormick F, Buettner R. 2000. 701 
The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific 702 
induction of caveolin-3 gene expression during embryonic development. J Biol Chem 703 
275:26245-51. 704 
56. Buskin JN, Hauschka SD. 1989. Identification of a myocyte nuclear factor that binds to 705 
the muscle-specific enhancer of the mouse muscle creatine kinase gene. Mol Cell Biol 706 
9:2627-40. 707 
57. Edmondson DG, Cheng TC, Cserjesi P, Chakraborty T, Olson EN. 1992. Analysis of the 708 
myogenin promoter reveals an indirect pathway for positive autoregulation mediated by 709 
the muscle-specific enhancer factor MEF-2. Mol Cell Biol 12:3665-77. 710 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 36 
58. Wheeler MT, Snyder EC, Patterson MN, Swoap SJ. 1999. An E-box within the MHC IIB 711 
gene is bound by MyoD and is required for gene expression in fast muscle. Am J Physiol 712 
276:C1069-78. 713 
59. Watanabe T, Takemasa T, Yonemura I, Hirabayashi T. 1997. Regulation of troponin T 714 
gene expression in chicken fast skeletal muscle: involvement of an M-CAT-like element 715 
distinct from the standard M-CAT. J Biochem 121:212-8. 716 
60. Sartorelli V, Webster KA, Kedes L. 1990. Muscle-specific expression of the cardiac 717 
alpha-actin gene requires MyoD1, CArG-box binding factor, and Sp1. Genes Dev 718 
4:1811-22. 719 
61. French BA, Chow KL, Olson EN, Schwartz RJ. 1991. Heterodimers of myogenic helix-720 
loop-helix regulatory factors and E12 bind a complex element governing myogenic 721 
induction of the avian cardiac alpha-actin promoter. Mol Cell Biol 11:2439-50. 722 
62. Harada A, Okada S, Konno D, Odawara J, Yoshimi T, Yoshimura S, Kumamaru H, 723 
Saiwai H, Tsubota T, Kurumizaka H, Akashi K, Tachibana T, Imbalzano AN, Ohkawa Y. 724 
2012. Chd2 interacts with H3.3 to determine myogenic cell fate. EMBO J 31:2994-3007. 725 
63. Melloul D, Marshak S, Cerasi E. 2002. Regulation of pdx-1 gene expression. Diabetes 51 726 
Suppl 3:S320-5. 727 
64. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, 728 
Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjostedt E, Lundberg E, 729 
Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk 730 
JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg 731 
M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlen M. 2014. 732 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 37 
Analysis of the human tissue-specific expression by genome-wide integration of 733 
transcriptomics and antibody-based proteomics. Mol Cell Proteomics 13:397-406. 734 
65. de la Serna IL, Ohkawa Y, Berkes CA, Bergstrom DA, Dacwag CS, Tapscott SJ, 735 
Imbalzano AN. 2005. MyoD targets chromatin remodeling complexes to the myogenin 736 
locus prior to forming a stable DNA-bound complex. Mol Cell Biol 25:3997-4009. 737 
66. Cao Y, Kumar RM, Penn BH, Berkes CA, Kooperberg C, Boyer LA, Young RA, 738 
Tapscott SJ. 2006. Global and gene-specific analyses show distinct roles for Myod and 739 
Myog at a common set of promoters. EMBO J 25:502-11. 740 
67. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, Klein WH. 1993. 741 
Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin 742 
gene. Nature 364:501-6. 743 
68. Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I, Nabeshima Y. 1993. 744 
Myogenin gene disruption results in perinatal lethality because of severe muscle defect. 745 
Nature 364:532-5. 746 
69. Dacwag CS, Bedford MT, Sif S, Imbalzano AN. 2009. Distinct protein arginine 747 
methyltransferases promote ATP-dependent chromatin remodeling function at different 748 
stages of skeletal muscle differentiation. Mol Cell Biol 29:1909-21. 749 
70. Hashimoto Y, King MM, Soderling TR. 1988. Regulatory interactions of calmodulin-750 
binding proteins: phosphorylation of calcineurin by autophosphorylated 751 
Ca2+/calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A 85:7001-5. 752 
71. Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, Wang W. 2000. A specificity and 753 
targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. 754 
Mol Cell Biol 20:8879-88. 755 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 38 
72. Albini S, Coutinho Toto P, Dall'Agnese A, Malecova B, Cenciarelli C, Felsani A, Caruso 756 
M, Bultman SJ, Puri PL. 2015. Brahma is required for cell cycle arrest and late muscle 757 
gene expression during skeletal myogenesis. EMBO Rep 16:1037-50. 758 
73. Ohkawa Y, Mallappa C, Vallaster CS, Imbalzano AN. 2012. Isolation of nuclei from 759 
skeletal muscle satellite cells and myofibers for use in chromatin immunoprecipitation 760 
assays. Methods Mol Biol 798:517-30. 761 
74. Wang Z, Zhai W, Richardson JA, Olson EN, Meneses JJ, Firpo MT, Kang C, Skarnes 762 
WC, Tjian R. 2004. Polybromo protein BAF180 functions in mammalian cardiac 763 
chamber maturation. Genes Dev 18:3106-16. 764 
75. Huang X, Gao X, Diaz-Trelles R, Ruiz-Lozano P, Wang Z. 2008. Coronary development 765 
is regulated by ATP-dependent SWI/SNF chromatin remodeling component BAF180. 766 
Dev Biol 319:258-66. 767 
76. He L, Tian X, Zhang H, Hu T, Huang X, Zhang L, Wang Z, Zhou B. 2014. BAF200 is 768 
required for heart morphogenesis and coronary artery development. PLoS One 769 
9:e109493. 770 
77. Chandler RL, Magnuson T. 2016. The SWI/SNF BAF-A complex is essential for neural 771 
crest development. Dev Biol 411:15-24. 772 
78. Raab JR, Resnick S, Magnuson T. 2015. Genome-Wide Transcriptional Regulation 773 
Mediated by Biochemically Distinct SWI/SNF Complexes. PLoS Genet 11:e1005748. 774 
79. Dallas PB, Yaciuk P, Moran E. 1997. Characterization of monoclonal antibodies raised 775 
against p300: both p300 and CBP are present in intracellular TBP complexes. J Virol 776 
71:1726-31. 777 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 39 
80. Hodges C, Kirkland JG, Crabtree GR. 2016. The Many Roles of BAF (mSWI/SNF) and 778 
PBAF Complexes in Cancer. Cold Spring Harb Perspect Med 6. 779 
81. Wu Q, Lian JB, Stein JL, Stein GS, Nickerson JA, Imbalzano AN. 2017. The BRG1 780 
ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer. 781 
Epigenomics 9:919-931. 782 
82. de La Serna IL, Carlson KA, Hill DA, Guidi CJ, Stephenson RO, Sif S, Kingston RE, 783 
Imbalzano AN. 2000. Mammalian SWI-SNF complexes contribute to activation of the 784 
hsp70 gene. Mol Cell Biol 20:2839-51. 785 
83. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation 786 
of Akt/PKB by the rictor-mTOR complex. Science 307:1098-101. 787 
84. Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, 788 
Gennert D, Li S, Livak KJ, Rozenblatt-Rosen O, Dor Y, Regev A, Yanai I. 2016. CEL-789 
Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biol 17:77. 790 
85. Kim D, Langmead B, Salzberg SL. 2015. HISAT: a fast spliced aligner with low memory 791 
requirements. Nat Methods 12:357-60. 792 
86. Anders S, Pyl PT, Huber W. 2015. HTSeq--a Python framework to work with high-793 
throughput sequencing data. Bioinformatics 31:166-9. 794 
87. Grun D, Kester L, van Oudenaarden A. 2014. Validation of noise models for single-cell 795 
transcriptomics. Nat Methods 11:637-40. 796 
88. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion 797 
for RNA-seq data with DESeq2. Genome Biol 15:550. 798 
89. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh 799 
H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors 800 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 40 
prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 801 
38:576-89. 802 
90. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-803 
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-8. 804 
91. Hernandez-Hernandez JM, Mallappa C, Nasipak BT, Oesterreich S, Imbalzano AN. 805 
2013. The Scaffold attachment factor b1 (Safb1) regulates myogenic differentiation by 806 
facilitating the transition of myogenic gene chromatin from a repressed to an activated 807 
state. Nucleic Acids Res 41:5704-16. 808 
92. Lee KS, Squillace RM, Wang EH. 2007. Expression pattern of muscleblind-like proteins 809 
differs in differentiating myoblasts. Biochem Biophys Res Commun 361:151-5. 810 
  811  on
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 41 
FIGURE LEGENDS 812 
Figure 1: Differential gene expression in myoblasts treated with Cn inhibitor. (A) Myotube 813 
formation in differentiating C2C12 cells is inhibited by FK506 treatment. The cells were fixed 814 
and analyzed by immunofluorescence staining using the anti–myosin heavy chain monoclonal 815 
Ab MF20 (green). The nuclei were visualized by DAPI staining (blue). Scale bar, 20 µm. (B) 816 
Volcano plots displaying differentially expressed genes between control (DMSO) treated and Cn 817 
inhibitor (FK506) treated differentiated C2C12 cells. The y–axis corresponds to the mean 818 
expression value of log 10 (p-value), and the x-axis displays the log2 fold change value. The red 819 
dots represent the up- and down- regulated transcripts between DMSO- and FK506-treated 820 
samples (False Discovery Rate (FDR)<0.05). The black dots represent the expression of 821 
transcripts that did not reach statistical significance (FDR>0.05).  (C) A Venn diagram displaying 822 
the number of genes up- and down- regulated by FK506 treatment at 24 and 72h post-823 
differentiation. (D) Transcription factor binding motifs identified within 1kb upstream of the TSS 824 
of genes differentially expressed in cells differentiated for 24 and 72h in the presence of FK506.  825 
Motifs displayed had p values ≤ 0.001. 826 
 827 
Figure 2: Enriched GO term analysis of differentially expressed genes. (A) Gene ontology 828 
analyses on genes differentially expressed by FK506 treatment for 24 and 72h post-829 
differentiation. (B) GO analysis of the biological processes shows differences between 830 
treatments (DMSO vs FK506) in muscle-related categories. 831 
 832 
Figure 3: Cluster analysis of differentially expressed genes at three differentiation time 833 
points in myoblasts treated with Cn inhibitor. (A) The heat map comparing differential 834 
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expression of 308 FK506 treatment-specific genes, categorized in four different clusters. Each 835 
column represents an experimental sample (times 0, 24 and 72h in differentiation medium 836 
(DM)) compared to the proliferating myoblast sample cultured in growth media (GM). Each 837 
row represents a specific gene. The colors range from yellow (high expression) to magenta 838 
(low expression) and represent the relative expression level value log2 ratios. (B) Kinetic 839 
expression patterns of the four clusters of genes. Lines represent the LOESS fitting for the 840 
relative expression for all genes in the cluster. The grey shading represents 95% confidence 841 
intervals. (C) Gene ontology analysis of differentially expressed genes within clusters 1-3 (C1, 842 
C2, C3) identified the top enriched GO terms with the corresponding enrichment p values and 843 
gene ratio.   844 
 845 
Figure 4: Cn regulates the expression of myogenic and other genes during myoblast 846 
differentiation. (A) Real time RT-PCR analysis validated expression changes of genes from 847 
clusters 1, 3 and 4 in FK506 treated cells. (B) RT-qPCR showed that expression of cluster 2 848 
genes Myog, Ckm, Myh4, Mymk, Tnnt3, Acta 1, and Cav 3 is down-regulated in FK506-treated 849 
C2C12 cells.  GM, proliferating cells in growth medium. DM, differentiation medium for the 850 
indicated time in hours (h). Data are the average of three or more independent samples 851 
performed in duplicate and are presented as the mean +/- SD. Expression in DMSO-treated GM 852 
samples were set to 1 and other values are relative to that sample. * p ≤ 0.05, ** p ≤ 0.001, 853 
***p≤ 0.0001 vs. GM or vehicle by Student’s t-test. 854 
 855 
Figure 5: FK506 treatment did not affect intracellular (A) or chromatin localization (B) of 856 
Cn and Brg1. Representative western blots of CnA, Brg1 and marker proteins in cytosolic, 857 
 o
n
 August 15, 2019 at UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
 43 
nuclear and chromatin fractions derived from proliferating and differentiating myoblasts. GM, 858 
proliferating cells in growth medium. DM, differentiation medium for the indicated time in 859 
hours.  860 
 861 
Figure 6: Cn binds to E-box containing regulatory sequences of myogenic genes during 862 
myoblast differentiation. Cn binding is reduced by FK506 treatment. (A) A schematic 863 
diagram of regulatory sequences of myogenic genes and localization of E-boxes and primers 864 
used in ChIP assays. (B) ChIP assays were performed for Cn binding in C2C12 cells. GM, 865 
proliferating cells in growth medium. DM, differentiation medium for the indicated time in hours 866 
(h). Relative enrichment was defined as the ratio of amplification of the PCR product normalized 867 
to control IgG and is shown relative to amplification of a non-specific control promoter region 868 
(Pdx1). The data are average of at least 3 independent experiments performed in triplicate +/- 869 
SD. * p ≤ 0.05, ** p ≤ 0.01, ***p≤ 0.001 vs. GM or vehicle by Student’s t-test. 870 
 871 
Figure 7: Cn inhibition reduces binding of the SWI/SNF subunits Brg1 (A), Baf170 and 872 
Baf250A (B) to E-box containing regulatory sequences of myogenic genes during myoblast 873 
differentiation. ChIP assays were performed for Brg1, Baf170 and Baf250A binding in C2C12 874 
cells. GM, proliferating cells in growth medium. DM, differentiation medium for the indicated 875 
time in hours (h). Relative enrichment was defined as the ratio of amplification of the PCR 876 
product normalized to control IgG and is shown relative to amplification of a non-specific 877 
control promoter region (Pdx1). The data are average of at least 3 independent experiments 878 
performed in triplicate +/- SD. * p ≤ 0.05, ** p ≤ 0.01, ***p≤ 0.001 vs. GM or vehicle by 879 
Student’s t-test. 880 
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 881 
Figure 8: Phosphomimetic mutation of Brg1 amino acids that are dephosphorylated by Cn 882 
reduces Cn and Brg1 binding to myogenic promoters in differentiating myoblasts. ChIP 883 
assays were performed for Cn or Brg1 binding in primary mouse myoblasts (C57Bl/6), in 884 
primary mouse myoblasts deleted for the gene encoding Brg1 (Brg1c/c), or in primary mouse 885 
myoblasts deleted for the gene encoding Brg1 that are expressing a wildtype (WT-Brg1), Brg1 886 
containing a non-phosphorylatable amino acid at Cn-targeted sites (SA-Brg1), or Brg1 887 
containing a phosphomimetic amino acid at Cn-targeted sites (SE-Brg1). Samples were collected 888 
from proliferating cells in growth medium (GM) or at 24h post-differentiation (DM). Relative 889 
enrichment was defined as the ratio of amplification of the PCR product normalized to control 890 
IgG and is shown relative to amplification of a non-specific control promoter region (Pdx1). The 891 
data are average of 3 independent experiments performed in triplicate +/- SD. * p ≤ 0.05, ** p 892 
≤ 0.01, ***p≤ 0.001 by Student’s t-test. 893 
 894 
Figure 9: Interaction between Cn and Brg1 is differentiation-dependent and is not affected 895 
by Cn inhibition or mutation of Brg1 amino acids that are targeted by Cn. (A) Co-896 
immunoprecipitation of Cn and Brg1 from cell lysates from 48h differentiated C2C12 cells 897 
treated with FK506. (B) Co-immunoprecipitation of Cn and Brg1 from cell lysates from 898 
proliferating and 24h differentiated primary mouse myoblasts. (C) Co-immunoprecipitation of 899 
Cn and Brg1 and MyoD and Brg1 from cell lysates from 24h differentiated primary C57Bl/6 900 
myoblasts and from primary mouse myoblasts deleted for the gene encoding Brg1 that are 901 
expressing a wildtype (WT-Brg1), Brg1 containing non-phosphorylatable amino acids at Cn-902 
targeted sites (SA-Brg1), or Brg1 containing phosphomimetic amino acids at Cn-targeted sites 903 
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(SE-Brg1). (D) Brg1 does not co-immunoprecipitate with Cn from Brg1 conditional myoblasts 904 
depleted for Brg1 and subjected to differentiation. Cell lysate from each IP (2.5% of input) 905 
served as a loading controls. The experiments were performed 3 times and representative gels are 906 
shown. 907 
 908 
Figure 10: Inhibition of Cn reduced MyoD binding to regulatory sequences of myogenic 909 
genes during myoblast differentiation. ChIP assays were performed for MyoD binding in 910 
C2C12 cells. GM, proliferating cells in growth medium. DM, differentiation medium for the 911 
indicated time in hours (h). Relative enrichment was defined as the ratio of amplification of the 912 
PCR product normalized to control IgG and is shown relative to amplification of a non-specific 913 
control promoter region (Pdx1). The data are average of at least 3 independent experiments 914 
performed in triplicate +/- SD. * p ≤ 0.05; ** p ≤ 0.01, *** p≤ 0.001 vs. GM or vehicle by 915 
Student’s t-test. 916 
 917 
Figure 11: Knockdown of Cn recapitulates findings made with Cn inhibitors and mutation 918 
of Brg1 amino acids that are targeted by Cn. (A) Western blot and RT-qPCR analysis showed 919 
shRNA-mediated knockdown of endogenous CnA in proliferating C2C12 cells. A scramble 920 
shRNA construct (shCtrl) was used as a control. (B) Representative images of myosin heavy 921 
chain staining in 72h differentiated cells expressing the control or Cn-targeting shRNAs. The 922 
cells were fixed and analyzed by immunofluorescence using an anti-myosin heavy chain mAb 923 
MF20 (green). The nuclei were visualized by DAPI staining (blue). Scale bar, 20 µm. (C) RT-924 
qPCR showed that expression of Myog, Ckm, Myh4, Cav3, Mymk, Tnnt3 and Acta1 is down-925 
regulated in Cn knockdown cells. GM, proliferating cells in growth medium. DM, differentiation 926 
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 46 
medium for the indicated time in hours (h). (D) RT-qPCR analysis validated expression of a 927 
representative gene from RNA seq analysis clusters 1, 3 and 4 and confirmed that their 928 
expression is changed in Cn knockdown cells compared to the scramble shRNA control. Data are 929 
the average of three independent samples performed in duplicate and are presented as the mean 930 
+/- SD. Expression in scramble shRNA expressing cells (panel A) or GM samples (panels C and 931 
D) were set to 1 and other values are relative to those samples. * p ≤ 0.05, ** p ≤ 0.001, 932 
***p≤ 0.0001 by Student’s t-test. 933 
 934 
Figure 12: Cn knockdown blocked binding of Cn (A), Brg1 (B) and MyoD (C) to E-box 935 
containing regulatory sequences of myogenic genes during myoblast differentiation. ChIP 936 
assays were performed for Cn, Brg1 and MyoD binding in control and Cn knockdown C2C12 937 
cells. Cn was knocked down by two independent shRNA constructs. GM, proliferating cells in 938 
growth medium. DM, differentiation medium for the indicated time in hours (h). Relative 939 
enrichment was defined as the ratio of amplification of the PCR product normalized to control 940 
IgG and is shown relative to amplification of a non-specific control promoter region (Pdx1). The 941 
data are average of at least 3 independent experiments performed in triplicate +/- SD. * p ≤ 0.05, 942 
** p ≤ 0.01, ***p≤ 0.001 by Student’s t-test. 943 
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